BRIM Biotechnology receives FDA agreement on Phase 3 clinical trial design for BRM421, BRIM's lead candidate for Dry Eye Disease, at End of Phase 2 Meeting
Taipei, Taiwan, 1st November 2022 / Sciad Newswire / BRIM Biotechnology, Inc. ("BRIM," TPEx 6885) is pleased to announce that it has received agreement from the US Food and Drug Administration (FDA) on the Phase 3 clinical trial design for its lead candidate for Dry Eye Disease (DED), BRM421, at the End of Phase 2 M...
Source: pharmiweb.com